Please sign in to follow a disease.
Correctsequence Therapeutics Co., Ltd
Clinical trials sponsored by Correctsequence Therapeutics Co., Ltd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Gene editing shot aims to tame deadly fat levels in rare disease Results expected Dec 2026 (estimated)
- Gene-Editing breakthrough? new therapy aims to stop sickle cell pain crises Results expected Dec 2026 (estimated)
-
Gene editing shot aims to tame deadly fat levels in rare disease
Disease control Recruiting nowThis early-stage trial tests a single infusion of CS-121, a gene editing therapy, in 15 adults with familial chylomicronemia syndrome (FCS), a rare condition causing extremely high blood fat levels. The therapy targets the APOC3 gene to lower triglycerides and reduce disease burd…
Early phase 1 • Sponsor: CorrectSequence Therapeutics Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Gene-Editing breakthrough? new therapy aims to stop sickle cell pain crises
Disease control Recruiting nowThis early-phase trial is testing a new treatment called CS-101 for severe sickle cell disease. It uses a person's own blood stem cells, which are gene-edited in a lab to correct the disease, then given back as a one-time infusion. The study will enroll 5 people aged 12 to 35 and…
Early phase 1 • Sponsor: CorrectSequence Therapeutics Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC